CuraGen Corp. (CRGN) announced that its Phase II Trial evaluating CR011-vcMMAE for the treatment of patients with unresectable Stage III or Stage IV melanoma met the efficacy criteria for advancement to the second stage of enrollment. CR011-vcMMAE is an antibody-drug conjugate comprised of a fully- human monoclonal antibody against glycoprotein NMB attached to a potent, synthetic drug monomethyl auristatin.
According to the company, out of the first six evaluable patients in the Phase II trial, one patient has had a confirmed objective response, as measured by RECIST criteria. As part of the Simon 2-Stage design the trial would be expanded to enroll 32 patients with a primary endpoint of objective response rate.
Further, the company expects enrollment in the study to complete by the end of 2008.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.